Can the fNIRS-derived neural biomarker better discriminate mild cognitive impairment than a neuropsychological screening test?

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20220417001

Enrollment

136

Registered

2022-04-17

Start date

2022-05-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cognitive impairment mild cognitive impairment functional near-infrared spectroscopy hemodynamic response biomarker

Interventions

According to the inclusion criteria, the MCI group consisted of patients with amnestic MCI.,The healthy control group did not show any health-related issues.

Diagnostic,Diagnostic

mild cognitive impairrment group,Healthy control group

Eligibility

Sex/Gender

All

Age

65 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) a subjective memory complaint (2) objective memory impairment confirmed by performances on the neuropsychological battery (Seoul Neuropsychological Screening Battery) (3) intact global cognitive function confirmed by the Korean version of Mini-Mental State Examination (4) independent activities of daily living (5) no dementia diagnosis confirmed by a physician

Exclusion criteria

Exclusion criteria: (1) the presence of psychiatric or neurological disorders (2) the presence of auditory or visual impairments

Design outcomes

Primary

Measure	Time frame
Korean version of the Montreal Cognitive Assessment (MoCA-K) at beginning point of the study Cognitive function,Brain activity at beginning point of the study a multi-channel fNIRS device	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

South Korea

Contacts

Public ContactJinHyuck Park

Soonchunhyang University

roophy@naver.com01064362419

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026